LungLife AI, INC Block Listing Six Monthly Return (2867Z)
May 15 2023 - 2:00AM
UK Regulatory
TIDMLLAI
RNS Number : 2867Z
LungLife AI, INC
15 May 2023
LungLife AI, Inc.
("LungLife" or the "Company")
Block Listing Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, makes the following six monthly update
on its block listing pursuant to AIM Rule 29 and Schedule 6 of the
AIM Rules for Companies:
Name of applicant: LungLife AI, Inc.
Name of scheme: 1. 2010 Stock Incentive Plan
2. 2020 Stock Incentive Plan
3. 2021 Omnibus Long-Term Incentive
Plan
----------------------------------------------
Number and class of securities 1,356,139 common shares of US
originally admitted: $0.0001 each
----------------------------------------------
Date of admission: 15 November 2021
----------------------------------------------
Period of return: From: 15 November To: 15 May 2023
2022
-------- ----------------- ----- --------------------
Balance of unallotted securities 1. 475,583
under scheme(s) from previous
return:
2. 201,374
3. 673,990
----------------------------------------------
Plus: The amount by which the 1. NIL
block scheme(s) has been increased 2. NIL
since the date of the last 3. NIL
return (if any increase has
been applied for):
----------------------------------------------
Less: Number of securities 1. NIL
issued/allotted under scheme(s) 2. NIL
during period (see LR3.5.7G): 3. NIL
----------------------------------------------
Equals: Balance under scheme(s) 1. 475,583
not yet issued/allotted at
end of period:
2. 201,374
3. 673,990
----------------------------------------------
Total number of securities
in issue at the end of the
period 25,485,982
----------------------------------------------
Name of contact: David Anderson, Chief Financial
Officer
Telephone number of contact: + 44 (0)20 7933 8780 or lunglifeai@walbrookpr.com
--------------------------------------------------
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Tel: +44 (0)20 7597 5970
Adviser & Broker)
Virginia Bull / Cameron MacRitchie
/ Lydia Zychowska
Goodbody (Joint Broker) Tel: +44 (0) 20 3841 6202 / +353
(1) 667 0420
Tom Nicholson / Stephen Kane
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Alice Woodings / Phillip Marriage Mob: 07407 804 654 / 07867 984 082
About LungLife
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
Our Purpose is to be a driving force in the early detection to
lung cancer. And our Vision is to invert the 20:80 ratio such that
in years to come at least 80% of lung cancer is detected early.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRGPUMWAUPWGGP
(END) Dow Jones Newswires
May 15, 2023 02:00 ET (06:00 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Apr 2023 to Apr 2024
